Literature DB >> 26763808

Therapeutic drug safety for Indigenous Australians: how do we close the gap?

Tilenka Thynne1, Genevieve M Gabb2.   

Abstract

Mesh：

Year:  2016        PMID： 26763808     DOI： 10.5694/mja15.00937

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  2 in total

1.  High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms.

Authors:  Andrew A Somogyi; Daniel T Barratt; Elizabeth J Phillips; Kylies Moore; Fahmida Ilyas; Genevieve M Gabb
Journal:  Br J Clin Pharmacol       Date:  2019-07-19       Impact factor: 4.335

2.  Pharmacogenomic analysis of a genetically distinct Indigenous population.

Authors:  Arvind Jaya Shankar; Sudhir Jadhao; Wendy Hoy; Simon J Foote; Hardip R Patel; Vinod Scaria; Brendan J McMorran; Shivashankar H Nagaraj
Journal:  Pharmacogenomics J       Date:  2021-11-25       Impact factor: 3.245
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.